Literature DB >> 12471061

Progressive retinal degeneration and dysfunction in R6 Huntington's disease mice.

Dominique Helmlinger1, Gaël Yvert, Serge Picaud, Karine Merienne, José Sahel, Jean-Louis Mandel, Didier Devys.   

Abstract

Huntington's disease (HD) and spinocerebellar ataxia type 7 (SCA7) belong to a group of progressive neurodegenerative diseases caused by polyglutamine (polyQ) expansions. SCA7 is the only one to display degeneration in the retina, a tissue usually spared in HD. We previously described a SCA7 transgenic retinal model expressing mutant full length ataxin-7 in rod photoreceptors. These mice develop a severe and characteristic retinopathy. We show here that R6 transgenic mice, which reproduce many features of HD, express mutant huntingtin in the retina leading to strong vision deficiencies and retinal dystrophy. These two different polyQ mouse models exhibit comparable early and progressive retinal degeneration and dysfunction. These abnormalities are reminiscent of other retinal degeneration phenotypes (in particular rd7/rd7 mice) where photoreceptor cell loss occurs. Retinopathy in R6 and R7E models can be monitored in living mice by ERG and fundus examination, which can facilitate in vivo evaluation of therapeutic agents in polyQ disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12471061     DOI: 10.1093/hmg/11.26.3351

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  24 in total

1.  Degeneration of ipRGCs in Mouse Models of Huntington's Disease Disrupts Non-Image-Forming Behaviors Before Motor Impairment.

Authors:  Meng-Syuan Lin; Po-Yu Liao; Hui-Mei Chen; Ching-Pang Chang; Shih-Kuo Chen; Yijuang Chern
Journal:  J Neurosci       Date:  2018-12-26       Impact factor: 6.167

2.  Preventing polyglutamine-induced activation of c-Jun delays neuronal dysfunction in a mouse model of SCA7 retinopathy.

Authors:  Karine Merienne; James Friedman; Masayuki Akimoto; Gretta Abou-Sleymane; Chantal Weber; Anand Swaroop; Yvon Trottier
Journal:  Neurobiol Dis       Date:  2006-12-26       Impact factor: 5.996

3.  Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease.

Authors:  A Jennifer Morton; Nigel I Wood; Michael H Hastings; Carrie Hurelbrink; Roger A Barker; Elizabeth S Maywood
Journal:  J Neurosci       Date:  2005-01-05       Impact factor: 6.167

4.  Immunoproteomic analysis of potential serum biomarker candidates in human glaucoma.

Authors:  Gülgün Tezel; Ivey L Thornton; Melissa G Tong; Cheng Luo; Xiangjun Yang; Jian Cai; David W Powell; Joern B Soltau; Jeffrey M Liebmann; Robert Ritch
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-13       Impact factor: 4.799

5.  Activation of gene transcription by heat shock protein 27 may contribute to its neuronal protection.

Authors:  Meyer J Friedman; Shihua Li; Xiao-Jiang Li
Journal:  J Biol Chem       Date:  2009-08-05       Impact factor: 5.157

6.  Optical coherence tomography findings in Huntington's disease: a potential biomarker of disease progression.

Authors:  Hannah M Kersten; Helen V Danesh-Meyer; Dean H Kilfoyle; Richard H Roxburgh
Journal:  J Neurol       Date:  2015-08-02       Impact factor: 4.849

7.  Retinal dysfunction in a presymptomatic patient with Huntington's disease.

Authors:  Jonelle Knapp; Dean A VanNasdale; Keith Ramsey; Julie Racine
Journal:  Doc Ophthalmol       Date:  2018-04-24       Impact factor: 2.379

8.  Selective neuronal requirement for huntingtin in the developing zebrafish.

Authors:  Tanya L Henshall; Ben Tucker; Amanda L Lumsden; Svanhild Nornes; Michael T Lardelli; Robert I Richards
Journal:  Hum Mol Genet       Date:  2009-09-29       Impact factor: 6.150

9.  Distinct and atypical intrinsic and extrinsic cell death pathways between photoreceptor cell types upon specific ablation of Ranbp2 in cone photoreceptors.

Authors:  Kyoung-In Cho; Mdemdadul Haque; Jessica Wang; Minzhong Yu; Ying Hao; Sunny Qiu; Indulekha C L Pillai; Neal S Peachey; Paulo A Ferreira
Journal:  PLoS Genet       Date:  2013-06-20       Impact factor: 5.917

10.  Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease.

Authors:  Mei Li; Douglas Yasumura; Aye Aye K Ma; Michael T Matthes; Haidong Yang; Gregory Nielson; Yong Huang; Francis C Szoka; Matthew M Lavail; Marc I Diamond
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.